SCHEMBL102836

SCHEMBL102836

[CH2]C(C)CCC(C)CCC(C)CCCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 1/20 0.43
LMNA P02545 2/20 0.38
DNM1 Q05193 2/20 0.36
OPRM1 P35372 1/20 0.35
ALDH1A1 P00352 3/20 0.32
TDP1 Q9NUW8 1/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 4/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP3A4 P08684 1/20 0.31
FDPS P14324 1/20 0.31
PRKD3 O94806 1/20 0.31
PRKCG P05129 1/20 0.31
PRKCB P05771 1/20 0.31
PRKCA P17252 1/20 0.31
PRKCH P24723 1/20 0.31
PRKCI P41743 1/20 0.31
PRKCE Q02156 1/20 0.31
PRKCQ Q04759 1/20 0.31
PRKCZ Q05513 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1971275 1.00 ACE2 (0.43) ACE2LMNADNM1OPRM1ALDH1A1
SCHEMBL1109989 0.92 ACE2 (0.52) ACE2LMNADNM1OPRM1TSHR
SCHEMBL28154768 0.90 ACE2 (0.55) ACE2LMNADNM1OPRM1TSHR
SCHEMBL7102064 0.90 ACE2 (0.55) ACE2LMNADNM1OPRM1TSHR
SCHEMBL28270177 0.90 ACE2 (0.55) ACE2LMNADNM1OPRM1TSHR
SCHEMBL7518034 0.90 ACE2 (0.55) ACE2LMNADNM1OPRM1TSHR
SCHEMBL7105806 0.90 ACE2 (0.55) ACE2LMNADNM1OPRM1TSHR
SCHEMBL28153716 0.90 ACE2 (0.55) ACE2LMNADNM1OPRM1TSHR
SCHEMBL1972553 0.90 LMNA (0.43) ACE2LMNADNM1OPRM1ALDH1A1
SCHEMBL11162195 0.90 LMNA (0.43) ACE2LMNADNM1OPRM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940943-B2 Cosmetic preparations COGNIS IP MANAGEMENT GMBH (DE) 2015-01-27 US disclosed
US-20130131188-A1 Cosmetic Preparations COGNIS IP MANAGEMENT GMBH (DE) 2013-05-23 US disclosed
EP-2426101-A1 Cosmetic preparations Cognis IP Management GmbH (DE) 2012-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131188-A1 Cosmetic Preparations CYP1B1, CBR1, ACOX3 ACE2 3825/4885LMNA 1943/4885DNM1 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.